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Introduction
“Periodic Fever Syndrome Masquerading as Eczematous
Dermatitis: Report of a D12E Mutation in TNFRSF1A”
Case Report
A 22 year-old woman presented with a six-year history of
periodic fevers, skin and joint disease. She presented with
an intermittent, intensely pruritic red rash on the torso
and extremities, associated with recurrent non-axial joint
pain and swelling, and periodic fevers lasting for days to
weeks. These symptoms were triggered by exposure to
heat, cold weather, dry air, and sweat. She denied eye or
gastrointestinal involvement. Physical exam revealed gen-
eralized, poorly demarcated, excoriated, erythematous
macules and patches. Skin histology showed minimal psor-
iasiform hyperplasia and mixed perivascular infiltrates.
Serum C-reactive protein, erythrocyte sedimentation rate,
and immunoglobulin D levels were within normal range.
Antinuclear antibody and rheumatoid factor tests were
negative. Genetic testing revealed a heterozygous nucleo-
tide substitution in the TNFRSF1A gene causing Tumor
Necrosis Factor-Associated Periodic Syndrome (TRAPS).
This mutation, namely D12E, results in substitution of an
Aspartic acid with a Glutamic acid. Her mother is an
asymptomatic heterozygote. After failing high-potency
topical steroids and antihistamines, she was started on eta-
nercept 100 mg weekly. Initial improvement of symptoms
was dramatic, but the effects waned after four months of
therapy. She was then switched to adalimumab 40 mg
every other week and reported marked reduction of her
skin manifestation and fevers. However, her condition
relapsed after six months of using adalimumab. At that
point, adalimumab was replaced with anakinra, an inter-
leukin 1 (IL-1) receptor antagonist, and the patient has
been reporting significant improvement in the past four
months.
Discussion
Patients with TNFRSF1A mutations affecting the cysteine
residues are predisposed to a more severe phenotype, with
fevers lasting for 23 days on average and many inflamma-
tory symptoms.[1] Thus far only three cases of D12E car-
riers have been described: one with short-lived fevers and
almost no other manifestations,[1] one with TRAPS phe-
notype,[2] and one also harboring a homozygous mutation
for and presenting with the Familial Mediterranean Fever
syndrome phenotype.[3] Our patient’s disease is likely
related to aberrant innate immunity. The fact that she and
her mother carry the same mutation, yet only one is symp-
tomatic, suggests incomplete penetrance of the allele.
Response to inhibition of IL-1 signaling is reassuring.
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